Agenus Inc
AGEN
Get informed when a big investor buys or sells
+ FollowMarket Cap$124.93M
Close$
$-6.07
297.7% downside
Current Fair Value
297.7% downsideOvervalued by 297.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $124.93 Million |
|---|---|
| Enterprise Value | $394.40 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 1.54 |
| Outstanding Shares | 37,941,000 |
Return
| Return on Equity | -29.20% |
|---|---|
| Return on Assets | 34.65% |
| Return on Invested Capital | -143.05% |
Valuation & Multiples
| P/E Ratio | 1.73 |
|---|---|
| PEG | -0.68 |
| Price to Sales | 1.02 |
| Price to Book Ratio | -0.44 |
| Enterprise Value to Revenue | 3.18 |
| Enterprise Value to EBIT | 4.39 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0.77 |
| Debt to Equity | -1.38 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$2.10
Average shareholder expectationRevenue Estimate
$129.50 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$34.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4183▲ 23.39% |
|---|---|
| Total Calls | 109,000▼ 19.91% |
| Total Puts | 45,600▲ 81.67% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 30.98%▼ 3.07% |
|---|---|
| Total Invested | $30.76M▼ 3.23% |
| Investors Holding | 90▼ 11.00% |
ESG Score
No data
About Agenus Inc
CEO: Garo Armen Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators , pa...